TY - JOUR
T1 - Fatigue is a common symptom in myelin oligodendrocyte glycoprotein antibody disease
AU - Ladakis, Dimitrios C.
AU - Gould, Jennifer
AU - Khazen, Jenny M.
AU - Lefelar, Julia M.
AU - Tarpey, Scott
AU - Bies, Charles J.
AU - Salky, Rebecca
AU - Fitzgerald, Kathryn C.
AU - Bhargava, Pavan
AU - Nourbakhsh, Bardia
AU - Sotirchos, Elias S.
N1 - Publisher Copyright:
© The Author(s), 2022.
PY - 2022/10
Y1 - 2022/10
N2 - Background: Unlike multiple sclerosis and neuromyelitis optica, the burden of fatigue in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is unclear. Objective: To compare fatigue levels between people with MOGAD and household controls (HC) and explore factors associated with fatigue severity. Methods: In a cross-sectional survey, data were collected from people with MOGAD and HC by utilizing an online questionnaire. Data elements included demographics, sleep quality measures, comorbidities, MOGAD characteristics, and fatigue severity measured by the Modified Fatigue Impact Scale (MFIS). We compared fatigue severity between MOGAD participants and HC and assessed the associations between demographic and disease characteristics and fatigue severity. Results: There were 180/283 MOGAD and 61/126 HC respondents. Compared to HC, people with MOGAD reported more severe fatigue, as measured by the MFIS total score (49.3 vs. 36.5; p < 0.001), and a larger proportion of MOGAD participants (75.6% vs. 44.3%; p < 0.001) were classified as fatigued. Among MOGAD participants, higher age (p = 0.04), history of bilateral optic neuritis (p = 0.02), and current use of acute treatment (p = 0.04) were independently associated with higher fatigue. Conclusions: Fatigue is common in people with MOGAD, and a history of bilateral optic neuritis, comorbid conditions, and ongoing disease activity appear to contribute to fatigue severity.
AB - Background: Unlike multiple sclerosis and neuromyelitis optica, the burden of fatigue in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is unclear. Objective: To compare fatigue levels between people with MOGAD and household controls (HC) and explore factors associated with fatigue severity. Methods: In a cross-sectional survey, data were collected from people with MOGAD and HC by utilizing an online questionnaire. Data elements included demographics, sleep quality measures, comorbidities, MOGAD characteristics, and fatigue severity measured by the Modified Fatigue Impact Scale (MFIS). We compared fatigue severity between MOGAD participants and HC and assessed the associations between demographic and disease characteristics and fatigue severity. Results: There were 180/283 MOGAD and 61/126 HC respondents. Compared to HC, people with MOGAD reported more severe fatigue, as measured by the MFIS total score (49.3 vs. 36.5; p < 0.001), and a larger proportion of MOGAD participants (75.6% vs. 44.3%; p < 0.001) were classified as fatigued. Among MOGAD participants, higher age (p = 0.04), history of bilateral optic neuritis (p = 0.02), and current use of acute treatment (p = 0.04) were independently associated with higher fatigue. Conclusions: Fatigue is common in people with MOGAD, and a history of bilateral optic neuritis, comorbid conditions, and ongoing disease activity appear to contribute to fatigue severity.
KW - ADEM
KW - Fatigue
KW - MFIS
KW - MOGAD
KW - Myelitis
KW - Optic neuritis
UR - http://www.scopus.com/inward/record.url?scp=85142000960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142000960&partnerID=8YFLogxK
U2 - 10.1177/20552173221131235
DO - 10.1177/20552173221131235
M3 - Article
C2 - 36407471
AN - SCOPUS:85142000960
SN - 2055-2173
VL - 8
JO - Multiple Sclerosis Journal - Experimental, Translational and Clinical
JF - Multiple Sclerosis Journal - Experimental, Translational and Clinical
IS - 4
ER -